Literature DB >> 18493705

Role of melatonin receptors in the effects of melatonin on BDNF and neuroprotection in mouse cerebellar neurons.

Marta Imbesi1, Tolga Uz, Hari Manev.   

Abstract

Although melatonin affects developing neurons and is neuroprotective, a role of melatonin receptors termed MT1 and MT2 in these actions is unclear. We investigated the effects of melatonin on the levels of the brain derived neurotrophic factor (BDNF) in the developing cerebellum and cerebellar granule cells (CGC) of wild-type (WT), MT1- and MT2-knockout mice. A model of low-potassium CGC toxicity was used to evaluate neuroprotection. A 14-day-old pups and CGC cultures were treated with melatonin; 0.01 mg/kg intraperitoneally and 1 nM in vitro, respectively. Treatment of WT pups and CGC with melatonin did not alter BDNF levels. The absence of MT2 but not MT1 receptors enabled melatonin to increase cerebellar and CGC BDNF content. Nanomolar melatonin was neuroprotective in MT2-knockout but not WT CGC. We propose that CGC from MT2-knockout mice could serve as a model for studying the influence of melatonin on human CGC, which express MT1 but not MT2 receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493705     DOI: 10.1007/s00702-008-0066-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  27 in total

Review 1.  Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors.

Authors:  Angélique Levoye; Ralf Jockers; Mohammed A Ayoub; Philippe Delagrange; Egemen Savaskan; Jean-Luc Guillaume
Journal:  Chronobiol Int       Date:  2006       Impact factor: 2.877

2.  Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.

Authors:  Egemen Savaskan; Mohammed A Ayoub; Rivka Ravid; Debora Angeloni; Franco Fraschini; Fides Meier; Anne Eckert; Franz Müller-Spahn; Ralf Jockers
Journal:  J Pineal Res       Date:  2005-01       Impact factor: 13.007

Review 3.  Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.

Authors:  Paula A Witt-Enderby; Nicholas M Radio; John S Doctor; Vicki L Davis
Journal:  J Pineal Res       Date:  2006-11       Impact factor: 13.007

4.  5-Lipoxygenase is required for proliferation of immature cerebellar granule neurons in vitro.

Authors:  T Uz; R Manev; H Manev
Journal:  Eur J Pharmacol       Date:  2001-04-20       Impact factor: 4.432

5.  The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system.

Authors:  Tolga Uz; Ahmet D Arslan; Murat Kurtuncu; Marta Imbesi; Mustafa Akhisaroglu; Yogesh Dwivedi; Ghanshyam N Pandey; Hari Manev
Journal:  Brain Res Mol Brain Res       Date:  2005-05-20

6.  Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats.

Authors:  T Uz; P Giusti; D Franceschini; A Kharlamov; H Manev
Journal:  Neuroscience       Date:  1996-08       Impact factor: 3.590

7.  Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone.

Authors:  Ying-Hui Wu; Jiang-Ning Zhou; Rawien Balesar; Unga Unmehopa; Aimin Bao; Ralf Jockers; Joop Van Heerikhuize; Dick F Swaab
Journal:  J Comp Neurol       Date:  2006-12-20       Impact factor: 3.215

Review 8.  The neuropathology of autism: where do we stand?

Authors:  C Schmitz; P Rezaie
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-26       Impact factor: 8.090

Review 9.  Molecular pharmacology, regulation and function of mammalian melatonin receptors.

Authors:  Margarita L Dubocovich; Moises A Rivera-Bermudez; Matthew J Gerdin; Monica I Masana
Journal:  Front Biosci       Date:  2003-09-01

10.  Abnormal melatonin synthesis in autism spectrum disorders.

Authors:  J Melke; H Goubran Botros; P Chaste; C Betancur; G Nygren; H Anckarsäter; M Rastam; O Ståhlberg; I C Gillberg; R Delorme; N Chabane; M-C Mouren-Simeoni; F Fauchereau; C M Durand; F Chevalier; X Drouot; C Collet; J-M Launay; M Leboyer; C Gillberg; T Bourgeron
Journal:  Mol Psychiatry       Date:  2007-05-15       Impact factor: 15.992

View more
  10 in total

1.  Distribution of MT1 melatonin receptor promoter-driven RFP expression in the brains of BAC C3H/HeN transgenic mice.

Authors:  E B Adamah-Biassi; Y Zhang; H Jung; S Vissapragada; R J Miller; M l Dubocovich
Journal:  J Histochem Cytochem       Date:  2013-09-18       Impact factor: 2.479

Review 2.  Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.

Authors:  Dmytro I Boiko; Anastasiia D Shkodina; Mohammad Mehedi Hasan; Mainak Bardhan; Syeda Kanza Kazmi; Hitesh Chopra; Prerna Bhutra; Atif Amin Baig; Andrii M Skrypnikov
Journal:  Neurochem Res       Date:  2022-06-11       Impact factor: 4.414

3.  Co-Administration of Progesterone and Melatonin Attenuates Ischemia-Induced Hippocampal Damage in Rats.

Authors:  Azim Hedayatpour; Maryam Shiasi; Hamidreza Famitafreshi; Farid Abolhassani; Parisa Ebrahimnia; Tahmineh Mokhtari; Gholamreza Hassanzaeh; Morteza Karimian; Bashir Nazparvar; Narges Marefati; Masoomeh Dehghan Tarzjani
Journal:  J Mol Neurosci       Date:  2018-09-04       Impact factor: 3.444

Review 4.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02

5.  Modulation of axonal sprouting along rostro-caudal axis of dorsal hippocampus and no neuronal survival in parahippocampal cortices by long-term post-lesion melatonin administration in lithium-pilocarpine model of temporal lobe epilepsy.

Authors:  Mahsa Kazemi; Saeed Shokri; Mahin Ganjkhani; Rostami Ali; Jafari Anarkooli Iraj
Journal:  Anat Cell Biol       Date:  2016-03-28

6.  Melatonin Modulates Dendrite Maturation and Complexity in the Dorsal- and Ventral- Dentate Gyrus Concomitantly with Its Antidepressant-Like Effect in Male Balb/C Mice.

Authors:  Gerardo Bernabé Ramírez-Rodríguez; Diana Montserrat Palacios-Cabriales; Leonardo Ortiz-López; Erika Montserrat Estrada-Camarena; Nelly Maritza Vega-Rivera
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

Review 7.  Melatonin-based therapeutics for neuroprotection in stroke.

Authors:  Kazutaka Shinozuka; Meaghan Staples; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

8.  Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis.

Authors:  Luciana Pinato; Sanseray da Silveira Cruz-Machado; Daiane G Franco; Leila M G Campos; Erika Cecon; Pedro A C M Fernandes; Jackson C Bittencourt; Regina P Markus
Journal:  Brain Struct Funct       Date:  2013-12-22       Impact factor: 3.270

Review 9.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

Review 10.  Melatonin-A Potent Therapeutic for Stroke and Stroke-Related Dementia.

Authors:  Nadia Sadanandan; Blaise Cozene; Justin Cho; You Jeong Park; Madeline Saft; Bella Gonzales-Portillo; Cesar V Borlongan
Journal:  Antioxidants (Basel)       Date:  2020-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.